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Tumor expression of the lymphangiogenic factor
VEGF-C is correlated with metastasis and poor prog-
nosis, and although VEGF-C enhances transport to
the draining lymph node (dLN) and antigen exposure
to the adaptive immune system, its role in tumor
immunity remains unexplored. Here, we demonstrate
that VEGF-C promotes immune tolerance in murine
melanoma. In B16 F10 melanomas expressing a
foreign antigen (OVA), VEGF-C protected tumors
against preexisting antitumor immunity and pro-
moted local deletion of OVA-specific CD8+ T cells.
Naive OVA-specific CD8+ T cells, transferred into
tumor-bearing mice, were dysfunctionally activated
and apoptotic. Lymphatic endothelial cells (LECs)
in dLNs cross-presented OVA, and naive LECs
scavenge and cross-present OVA in vitro. Cross-
presentingLECsdrove theproliferationandapoptosis
of OVA-specific CD8+ T cells ex vivo. Our findings
introduce a tumor-promoting role for lymphatics in
the tumor and dLN and suggest that lymphatic endo-
thelium in the local microenvironmentmay be a target
for immunomodulation.
INTRODUCTION
It is now recognized that tumor cells can express immunogenic
antigens through mutation and that adaptive immune responses
can be mounted in tumor-bearing hosts (Baitsch et al., 2011;
Munn and Mellor, 2006; Zippelius et al., 2004). However, while
the functional activation of T cells by antigen-presenting cells
usually occurs in secondary lymphoid organs, tumors and their
draining lymph nodes (dLNs) can locally render such antigen-
specific T cells ineffective (Baitsch et al., 2011; Munn andMellor,
2006; Thaunat et al., 2010; Zippelius et al., 2004).
Expression of the lymphangiogenic growth factor VEGF-C in
the tumor promotes LNmetastasis (Skobe et al., 2001; Tammelaand Alitalo, 2010; Yanai et al., 2001) and increased lymph
drainage to the dLN (Harrell et al., 2007). While tumor-associated
lymphangiogenesis was earlier considered to passively trans-
port invasive tumor cells to the dLN, more recent studies
demonstrate an active role for lymphatics and their associated
chemokines in promoting tumor progression and metastasis to
the dLN (Issa et al., 2009; Kerjaschki et al., 2011; Shields et al.,
2010). Additionally, lymphatic vessels physically link the tumor
immune status to its dLN through cell and antigen transport
(Clement et al., 2010; Randolph et al., 2005) and the dLN
plays an important role in balancing adaptive immunity and local
peripheral tolerance (Cohen et al., 2010; Fo¨rster et al., 2008;
Lund and Swartz, 2010; Reynoso et al., 2009). However, to
date, the effects of VEGF-C and tumor-associated lymphangio-
genesis on host antitumor immunity remain unexplored.
Here, we demonstrate that VEGF-C and associated LN lym-
phangiogenesis suppress antitumor immunity through mecha-
nisms that include local deletional tolerance, which in turn drives
disease progression and metastasis. VEGF-C-expressing (lym-
phangiogenic) tumors were protected from vaccine-induced
immunity and promoted naive T cell deletion in sentinel dLN.
Lymphatic drainage bathes the lymphatic vessels and dLN
in soluble antigen (Clement et al., 2011; Sixt et al., 2005), and
we show in B16 melanoma that VEGF-C-activated lymphatic
endothelial cells (LECs) can take up and cross-present tumor
antigen, leading to dysfunctional activation of CD8+ T cells.
This mechanism of antigen cross-presentation by LECs is
distinct from the promiscuous presentation of endogenous
self-antigens by LN stromal cell subsets (Cohen et al., 2010;
Fletcher et al., 2010) and may constitute a new target for cancer
immunotherapy.
RESULTS
VEGF-C and Tumor Lymphangiogenesis Protects
against Preexisting, Vaccine-Induced Immunity
Malignant melanoma growth and metastasis have been corre-
lated with VEGF-C expression and lymphatic density in humans,
and both human and murine melanomas are antigenic but
employ active mechanisms of immune evasion (Anichini et al.,Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authors 191
Figure 1. VEGF-C Protect against Preexisting Antitumor Immunity in B16-F10 Melanomas
(A) Location of tumor inoculation with associated draining lymph node (dLN, axillary, and brachial) and contralateral non-dLN.
(B) Lymphatic vessels in the tumor (left) and dLN (right) at day 12. Bar, 50 mm.
(C) OVA vaccination scheme with lipopolysaccharide (LPS) adjuvant and 500 mg anti-VEGFR3 (mF4-31C1 #).
(D) Growth profiles for control OVA and OVA/VEGF-C+ B16 tumors after vaccination and anti-VEGFR3 treatment.
(E–G) Representative plots (E) and quantification (F) of OVA-specific CD8a+ T cells infiltrating the tumor (left) or draining lymph node (right) and in the blood (G).
Shown are medians and whiskers show range.
*p% 0.05, **p% 0.01, nR 8.2004; Ferguson et al., 2008). To address the potential roles
of VEGF-C in modulating host antitumor immunity, we ex-
pressed VEGF-C along with chicken ovalbumin (OVA) in B16-
F10 melanoma cells (Figures S1A–S1C) and compared host
immune responses in immune competent, syngenic C57BL/6
mice.
Tumor cells were implanted intradermally (i.d.) and dorsolater-
ally to define drainage to a single set of sentinel lymph nodes192 Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authors(axillary and brachial, Figure 1A). Though primary tumor growth
was largely unaffected by VEGF-C expression (Figures S1D
and S1E), as expected, VEGF-C+ tumors induced lymphangio-
genesis around the tumor and in the dLN and drove increased
metastasis to the dLNs (Figure 1B; Figures S1F and S1G).
Furthermore, VEGF-C+ B16 tumors demonstrated increased
fluid drainage and dendritic cell (DC) migration from the tumor
to the dLN (Figures S1H and S1I).
VEGF-C+ tumors contained more CD45+ immune cell infil-
trates, including T cells (Figures S2A and S2B). These immune
infiltrates, however, contained more regulatory T (TReg) cells but
fewer antigen-specific CD8 T cells (Figures S2C and S2D). Other
immune regulatory subsets preferentially recruited to VEGF-C+
tumors included myeloid-derived suppressor cells (CD11b+F4/
80GR1hi) and CD11c+CD11b+CD8a DCs (Figure S2E).
Next, we wondered whether VEGF-C could provide protection
against a strong immune response and what role, if any, local
lymphatics may play. LN stromal cells, including LECs, promis-
cuously express peripheral tissue antigens (such as tyrosinase)
to maintain peripheral tolerance (Cohen et al., 2010; Fletcher
et al., 2010), making it difficult to assess new mechanisms of
tolerance above this background. Therefore, we introduced
a foreign antigen (OVA) into the tumor cells, and vaccinated
mice prior to implantation to generate systemic cytotoxic T
lymphocytes (CTLs) against the tumor. In this way, we could
distinguish newly formed tolerance to a tumor-associated
antigen from preexisting tolerance due to endogenous self-
antigen presentation.
To determine the potential protective effects of tumor VEGF-C
against preexisting immunity, we vaccinated mice with OVA and
lipopolysaccharide (LPS) as an adjuvant 10 days before tumor
implantation (Figure 1C). As expected, this vaccination strongly
inhibited the growth of OVA tumors (Figure 1D, left). Remarkably,
however, vaccination had no effect on the growth of OVA/
VEGF-C+ tumors (Figure 1D, right). Both in the tumor and dLN,
mice bearing OVA/VEGF-C+ tumors showed a decrease in the
local infiltration of OVA (pentamer)-specific CD8+ T cells (Figures
1E and 1F), even while these antitumor CTLs were circulating at
similar levels in all vaccinated mice (Figure 1G). This VEGF-
C-mediated local suppression of vaccine-induced immunity
was dependent upon VEGFR3 signaling, since mice that were
additionally treated with mF4-31C1, a neutralizing antibody
against VEGFR-3, during tumor growth were susceptible to the
vaccine (Figure 1D). Additionally, VEGFR-3 inhibition further
enhanced antitumor CTLs in the tumor and dLN in control OVA
tumors (Figure 1F), suggesting that endogenous levels of
VEGF-C found in the stroma, likely due to CD11b+ macrophage
infiltrates (Figure S2F; Kluger and Colegio, 2011), may also help
suppress host immunity.
VEGF-C+ Tumors Suppress Naive T Cell Activation
in the Draining Lymph Node
Given the observed suppression of antigen-specific T cell
responses locally within the tumor and dLN, we then asked
whether these CD8+ T cells were being inhibited during their
activation. We injected carboxyfluorescein succinimidyl ester
(CFSE)-labeled naive CD8+ T cells bearing the receptor for the
OVA peptide (SIINFEKL)-loaded major histocompatibility class I
(MHC I) complex (OT-I) into tumor-bearing mice (CD45.1) and
assessed their activation in the dLN (Figure 2A). When trans-
ferred into unvaccinated tumor-bearing hosts at day 9, OT-I cells
demonstrated altered homing to OVA/VEGF-C+ tumors com-
pared toOVA tumors (Figures 2B and 2C). The presence of highly
proliferated CFSECD45.2+CD8a+ cells, and absence of CFSE+
(unproliferated) cells, in OVA B16 tumors suggested that prolifer-
ation and activation of transferred OT-I cells primarily occurreddistal to the tumor. Significantly fewer proliferated but more
unproliferated cells were detected in OVA/VEGF-C+ compared
to OVA B16 tumors (Figure 2C). These infiltrates were function-
ally assessed two days later and those accumulating in OVA/
VEGF-C+ tumors produced significantly less IFN-g (Figure S3A)
and had lower expression of T cell activation markers CD25
and CD69 (Figure S3B).
Next, we asked whether naive OT-I cells were differentially
activated in dLNs of OVA and OVA/VEGF-C+ tumors, thereby
leading to the observed changes in tumor infiltration. We found
that while the extent of OT-I cell proliferation in OVA/VEGF-C+
dLN was similar to that in OVA dLNs (Figures 2D and 2E),
their functional activation was impaired. Specifically, after 3 or
5 days, activated OT-I cells in the dLNs of OVA/VEGF-C+ tumors
secreted less IFN-g, were progressively more apoptotic com-
pared to those in the dLN of OVA tumors, and expressed lower
levels of the activation markers CD25 and CD69 (Figures 2F
and 2G; Figures S3C and S3D). In contrast, transferred naive
OT-I T cells were activated and less apoptotic when mice were
treated with anti-VEGFR-3 blocking antibodies (Figure 2G).
These data indicate a dysfunctional T cell response in dLN of
OVA/VEGF-C+ tumors compared to OVA tumors.
Tumor-Associated Lymphatics Directly Interact with
T Cells and Present Tumor Antigen Peptides on MHC I
In Vivo
Tumors were sectioned and stained 3 days following adoptive
transfer to localize the T cell infiltrate within the stroma. We
observed an increased infiltration of transferred OT-I T cells, par-
ticularly localized and clustered around peritumoral lymphatic
vessels, in OVA/VEGF-C+ versus OVA tumors (Figure 3A), sug-
gesting that VEGF-C activated LECs might directly alter the
CD8+ T cell response. Since LN LECs present endogenous
peripheral tissue antigens on MHC I molecules (Cohen et al.,
2010), we asked whether VEGF-C-activated LECs in the tumor
and dLN might extend this tolerogenic function to scavenge
and cross-present exogenous antigen for T cell deletion. To
address this, we implanted OVA tumors into chimeric mice
whose CD45+ cells lacked MHC I (Figures S4A and S4B), and
then adoptively transferred naive OT-I cells after 9 days. Despite
the lack of cross-presentation by professional APCs in these
mice, OT-I cells still proliferated in the dLNs of OVA-expressing
tumors (Figures 3B and 3C), indicating that the exogenous
MHC I peptide of OVA was presented on MHC I molecules of
stromal (CD45) cells in the dLN.
To determine specifically which LN stromal cells were
presenting antigen, we sorted the stromal cell populations from
the dLNs in tumor-bearing wild-type mice after 14 days (Fig-
ure S4C). Ex vivo, LECs (gp38+CD31+) and blood endothelial
cells (BECs, gp38CD31+) significantly induced OT-I pro-
liferation, while fibroblastic reticular cells (FRCs, gp38+
CD31) did not (Figures 3D and 3E). Consistent with these
results, LECs in OVA-expressing tumors and their dLNs were
positive for 25d1.16 (an antibody that specifically recognizes the
MHC I-SIINFEKL peptide complex), and presented more SIIN-
FEKL per cell in VEGF-C-expressing tumors (Figure 3F). These
data suggest that LECs may take up and process OVA for
cross-presentation on MHC I molecules.Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authors 193
Figure 2. CD8+ T Cells Activated in Lymph Nodes Draining VEGF-C+ Tumors Are Dysfunctional and Apoptotic
(A) Scheme for OT-I adoptive transfer. After 9 days tumor growth, 106 naive CD8+ OT-I cells were injected i.v. with 500 mg mF4-31C1 (#).
(B–E) Representative plots (B and D) and quantification (C and E) of CFSE-labeled OT-I cells (CD45.2+CD8a+) 3 days after transfer in the tumor (B and C) or
draining LN (D and E).
(F) IFN-g production (left) and annexin V (AnV, right) binding by transferred OT-I cells with proliferation.
(G) IFN-g (left) and AnV (right) as % OT-I cells present within the draining LN. Shown are medians and whiskers show range.
*p% 0.05, **p% 0.01, nR 8.Lymphatic Endothelial Cells Cross-Present Antigen
and Cross-Tolerize T Cells In Vitro
Prenodal lymph contains preprocessed peptides fromperipheral
tissues that can bind directly to MHCI molecules expressed on194 Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authorsthe cell surface (Clement et al., 2011). In order to demonstrate
that LECs can also directly process and cross-present antigens
we exposed ex vivo LN stromal cell cultures (Fletcher et al.,
2010), which were predominantly FRCs and LECs (Figures S4D
and S4E), to nanoparticles coupled with a longer version of the
OVA MHC I peptide (SIINFEKL) designed to require uptake and
processing for presentation on MHCI (NPssCOVA250-264) (Hiro-
sue et al., 2010). The MHCI-SIINFEKL complex was detected
on B16 F10 melanoma cells (negative control) only when ex-
posed to the peptide but not the nanoparticle-coupled peptide.
However, LECs and bone marrow-derived DCs (BMDCs, posi-
tive control) displayed the complex after exposure to the nano-
particle-coupled peptide (Figures 4A and 4B), indicating a
capacity for antigen processing and cross-presentation. These
LECs, when sorted and rinsed following NPssCOVA250-264 expo-
sure, could induce significant proliferation of naive OT-I cells
(Figures 4C and 4D). As expected, proliferation was significantly
less than that induced by BMDCs; however, LEC-stimulated
T cells expressed less IFN-g (Figure 4E) and bound more
annexin V than BMDCs or splenocytes (Figures 4F and 4G).
Together, these data demonstrate that LN LECs can cross-
present tumor antigen and directly suppress tumor-specific
CD8 T cells by inhibiting cytotoxic function and inducing
apoptosis.
DISCUSSION
Here we introduce VEGF-C as a protumor immunomodulatory
factor and identified a new immunosuppressive role for lym-
phatic endothelial cells, to scavenge and cross-present antigens
for direct suppression of CTLs. This adds to our understanding
of VEGF-C as a tumor metastasis promoter by linking it to
tumor immune escape, often considered critical to tumor
progression.
Hundreds of studies have now established the clinical rele-
vance of VEGF-C in the tumor microenvironment (summarized
by Tammela and Alitalo, 2010). In human cancer, VEGF-C
expression correlates with lymph node metastasis and poor
prognosis (Padera et al., 2002; Wong et al., 2005), while VEGF-
C overexpression in murine tumors induces metastasis (Man-
driota et al., 2001; Padera et al., 2002; Skobe et al., 2001;
Wong et al., 2005; Yanai et al., 2001) and blocking VEGFR-3
signaling decreases tumor invasion and metastasis (He et al.,
2002; Roberts et al., 2006). However, although tumor immunolo-
gists have long appreciated the importance of the sentinel LN
in suppressing antitumor immune responses (Munn and Mellor,
2006), the roles of tumor VEGF-C and lymphangiogenesis,
which enables and enhances communication between the tumor
and the dLN, in modulating tumor immunity remain largely
unexplored.
The local inhibition of activated CD8+ T cells by LECs in the
dLN is consistent with recent studies in humanmelanoma, where
exhausted CD8+ T cells were found in primary and secondary
tumors while active CTLs remained in circulation (Baitsch
et al., 2011). A major function of the LN is to maintain and regu-
late immune homeostasis and peripheral tolerance (Fo¨rster et al.,
2008; Turley et al., 2010), and LN stromal cells delete autoreac-
tive T cells through promiscuous presentation of peripheral self-
antigens by stromal cells (Cohen et al., 2010; Fletcher et al.,
2010). In addition, lymphatic drainage carries soluble antigen,
membrane bound vesicles, cytokines and cells to the LN where
it flows through an extensive collagen conduit system, providingantigen to the largely tolerogenic and immature local APC popu-
lation (Munn and Mellor, 2006; Sixt et al., 2005). This constant
sampling of peripheral antigens in the local dLN is likely impor-
tant for maintaining tolerance, as when lymphatic drainage was
locally blocked in the skin, tolerance to skin contact hypersensi-
tizing agents could not be induced (Friedlaender and Baer,
1972). Therefore it is possible that tumors may hijack such toler-
ance-maintaining functions of the dLN to suppress cytotoxic
immune responses.
VEGF-C-enhanced lymph flow may also promote tumor
progression in other ways. First, it may increase interstitial flow
in the tumor stroma, which itself can promote invasion through
fibroblast activation (Shieh et al., 2011), matrix stiffening (DuFort
et al., 2011), and biasing chemokine gradients (Fleury et al.,
2006; Shields et al., 2007). Additionally, it may help to prime
the premetastatic niche, which prepares the dLN for tumor cell
invasion. Importantly, premetastatic tumor-dLNs, but not normal
LNs, in humans were found to contain bone marrow progenitor
cells associated with the metastatic niche (Peinado et al.,
2011), implicating lymphatic drainage from the tumor in driving
these changes. Furthermore, enhanced flow and delivery of
peripheral antigens to LN LECs (Clement et al., 2011) may
promote their newly proposed suppressive functions (Cohen
et al., 2010; Liao et al., 2011; Lukacs-Kornek et al., 2011).
Our finding that dLN LECs cross-present draining, exog-
enous antigen for CD8 T cell deletion is reminiscent of liver
sinusoidal endothelial cells (LSECs). Self-antigen presentation
on MHCI is defined for many cell types for ‘‘self’’ identification,
but scavenging, processing, and cross-presentation of exoge-
nous antigens are functions attributed typically to specialized
antigen-presenting cells. LSECs are constantly exposed to
foreign antigens from food and they scavenge and cross-
present these antigens to promote CD8 T cell clustering and
suppression (Schurich et al., 2010; von Oppen et al., 2009). An
important mechanism of LSEC suppression is T cell adhesion to
the endothelium and migratory arrest (von Oppen et al., 2009),
and we frequently observed OVA-specific T cells adhering to
lymphatic vessels surroundingOVA/VEGF-C+ tumors (Figure 3A).
Lymphatic antigen presentation is a newly described mecha-
nism by which tumors evade host immunity through the direct
suppression of tumor-specific CD8 T cells by LECs. This immu-
nomodulatory function may have evolved to help maintain
peripheral tolerance after injury and to prevent autoimmunity in
chronic inflammation, where macrophages produce VEGF-C
that can drive local and dLN lymphangiogenesis. In such condi-
tions, lymphatic vessels can actively modulate flow to the dLN
(Harrell et al., 2007; Miteva et al., 2010), thereby linking lymphatic
transport function to host immunity. A recent study demon-
strated that IFN-g and cytotoxic T cells negatively regulate
lymphangiogenesis (Kataru et al., 2011). Our observed enhance-
ment of antigen-specific CD8 tumor infiltration following anti-
VEGFR3 treatment is consistent with this, suggesting that
anti-lymphangiogenic therapy, even with endogenous levels of
VEGF-C, may enhance antitumor responses. Therefore a di-
chotomy of function seems to exist whereby lymphangiogenesis
inhibits CTLs, while CTLs and their proinflammatory cytokines
inhibit lymphangiogenesis leading to a balance between inflam-
mation and peripheral tolerance.Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authors 195
Figure 3. Lymphatic Endothelial Cells Interact with CD8+ T Cells In Vivo and Cross-Present Tumor Antigen
(A) Immunofluorescence showing OVA-specific T cells interacting with LECs (arrows) in the stroma of OVA and OVA/VEGF-C+ tumors. Bar, 100 mm.
(B and C) Representative plots (B) and quantification (C) of OT-I CD8+ T cell proliferation in draining lymph nodes (dLN) of tumor-bearing mice after adoptive
transfer. b2m/:wt (b2m:wt) chimeric mice lack MHC I expression in hematopoietic but not stromal cells.
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Figure 4. Lymphatic Endothelial Cells Cross-Present Antigen to Induce Dysfunctional T Cell Activation
(A and B) Representative plots (A) and geometric means (B) of MHCI/SIINFEKL complex (25d1.16) on cultured lymph node (LN) LECs, dendritic cells (BMDCs),
and B16-F10 tumor cells after 24 hr pulse with NPssCOVA250-264 or SIINFEKL.
(C and D) Representative plots (C) and quantification (D) of OT-I CD8+ T cell proliferation after coculture with antigen-pulsed LECs.
(E) IFN-g production (by intracellular cytokine staining) in OT-I cells stimulated by antigen-presenting BMDCs or LECs.
(F and G) Representative plots (F) and quantification (G) of Annexin V (AnV) binding on OT-I cells after coculture with freshly sorted tumor-draining LN LECs or
splenocytes reexposed to SIINFEKL antigen ex vivo.
Shown are means ± SEM. *p% 0.05, **p% 0.01, nR 3.The relative importance of antigen presentation by LECs in
VEGF-C-driven tumor tolerance remains to be determined, as
well as whether LECs and VEGF-C play similar immunomodula-
tory functions in contexts other than the unique microenviron-(D and E) Representative plots (D) and quantification (E) of ex vivo OT-I cell prolife
from naive mice with SIINFEKL were used as a positive control.
(F) MHC I-SIINFEKL complex (25d1.16) on LECs (gp38+CD31+) in the tumor and
Shown are means ± SEM. *p% 0.05, **p% 0.01, nR 8.ment of aggressive tumors. Nevertheless, we introduce the
lymphatic endothelium as an active modulator of antitumor
immunity and suggest that it may be targetable in strategies to
improve cancer immunotherapy.ration after coculture with cells isolated dLN of VEGF-C+ tumors. Splenocytes
dLN.
Cell Reports 1, 191–199, March 29, 2012 ª2012 The Authors 197
EXPERIMENTAL PROCEDURES
More detailed information can be found in the Extended Experimental
Procedures. All procedures were approved by the Veterinary Authorities of
the Canton Vaud according to Swiss Law.
Ovalbumin Immunization
Mice received 10 mg lipopolysaccharide (LPS) as a negative control or 10 mg
LPS plus 10 mg OVA (grade IV, Sigma) in two i.d. doses 25 ml per foreleg.
Ten days later, 5 3 105 B16-F10 OVA or OVA/VEGF-C+ tumor cells in 50 ml
were inoculated i.d. and dorsolaterally, and a vaccine boost (identical to the
first) was administered again on day 15. In some mice, 500 mg anti-VEGFR-3
neutralizing antibody (mF4-31C1, ImClone/Eli Lilly) was administered at
days 0, 4, and 8 days after tumor inoculation.
OT-I Adoptive Transfer and Coculture
Splenic CD8 T cells were isolated by negative magnetic cell sorting (CD8a+
T cell isolation kit II, Miltenyi Biotech). Purified CD8+ OT-I cells were labeled
with 1 mM CFSE and injected i.v. into tumor-bearing mice (1 3 106 cells in
200 ml). To measure IFN-g production, mice were given 250 mg brefeldin A
intraperitoneally (i.p.) 6 hr prior to sacrifice (Thompson et al., 2010). In
ex vivo experiments, naive OT-I CD8+ T cells were directly cocultured with
sorted lymph node stromal cells at a 1:3 ratio for 3–4 days in vitro.
Ex Vivo LEC Sorting and Coculture
On day 7 of LEC/FRC culture, cells were stimulated 24 hr prior to sorting with
(1) synthetic nanoparticles disulfide-conjugated to an N-terminally elongated
SIINFEKL peptide (CSGLEQLESIINFEKL (Hirosue et al., 2010), (2) SIINFEKL,
or (3) empty nanoparticles as controls; in all cases, 10 nM SIINFEKL was
delivered. LECs (CD45 gp38+ CD31+) were sorted with a FACS Vantage
SE. DIVA were cocultured with CFSE-labeled naive CD8+ OT-I T cells (1:10)
for 4 days, which were then analyzed by flow cytometry for IFN-g and
Annexin-V binding (see Extended Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.celrep.
2012.01.005.
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